Role of the MET Oncogene in Human Colorectal Cancer - A Translational Study

NCT ID: NCT02238821

Last Updated: 2017-03-03

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 60 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2007-10-31
• Study Completion Date: 2016-12-31

Brief Summary

The MET oncogene is known to sustain the Trousseau's syndrome in murine experimental models, featuring association of carcinogenesis with a blood procoagulant disorder. MET is frequently overexpressed in colorectal cancer, a tumor where venous thromboembolism (VTE) may occur in association with poor prognosis, but the biological and genetic factors that cause VTE are still obscure.

The Investigators propose to study whether in patients harboring a surgically resectable colorectal cancer the MET oncogene is expressed and may be associated with a blood thrombophilic condition that favors the onset of VTE.

These data would have two main implications: (i) for the first time, a direct genetic link between the MET oncogene and a procoagulant disorder would be demonstrated in humans; (ii) the procoagulant alterations would have diagnostic/prognostic significance for the identification of patients at risk for poor outcome, and implementation of appropriate therapeutic protocols.

Conditions

Colorectal Cancer

Study Design

• Observational Model Type: OTHER
• Study Time Perspective: PROSPECTIVE

Study Groups

resectable colorectal cancer

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• age > or = 18;
• age < or = 80;
• Clinical diagnosis of colorectal tumor by CT, MRI or endoscopy;
• surgically resectable tumor;

Exclusion Criteria

• Inclusion in other clinical protocols requiring administration of anticoagulant drugs;
• Life expectancy < 6 month;
• Clinical diagnosis of thrombophilic condition by laboratory analysis;
• Previously implanted Central Venous Catheter;
• Previous or concomitant second neoplasia;
• Clinical diagnosis of kidney, liver or heart failure;
• Inflammatory markers alteration associated with disease unrelated to neoplasia (infection, connective tissue disease etc);
• Severe hemostasis disorder;

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Fondazione del Piemonte per l'Oncologia

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Paolo M Comoglio, MD

Role: STUDY_DIRECTOR

Fondazione del Piemonte per l'Oncologia

Locations

Fondazione del Piemonte per l'Oncologia

Candiolo, TO, Italy

Countries

Italy

Other Identifiers

MET/colon 06

Identifier Type: -

Identifier Source: org_study_id